|

Fulvestrant Clinical Trials

57 actively recruiting trials across 25 locations

▼ -4 trials since August 2026

Also known as: Experimental group, FASLODEX®, Faslodex, Faslodex(ICI 182,780), Faslodex, +10 more

Pipeline

Phase 1: 14Phase 2: 21Phase 3: 7Phase 1/2: 13

Top Sponsors

  • Hoffmann-La Roche5
  • Pfizer3
  • Novartis Pharmaceuticals3
  • Fudan University3
  • Eli Lilly and Company3

Indications

  • Cancer57
  • Breast Cancer52
  • Metastatic Breast Cancer14
  • Advanced Breast Cancer10
  • HER2-negative Breast Cancer6

Other12 trials

A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy
Phase 2
A Phase II Clinical Study of the Efficacy and Safety of Culmerciclib Rechallenge in HR-positive, HER2-negative Breast Cancer Patients With Resistance to First-line Endocrine Therapy.
Phase 2
A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer
N/A
A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer
Phase 3
A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy
Phase 2
Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor
Phase 2
Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer
Phase 3
Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC
Phase 2
Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer
Phase 2
Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor
Phase 2
Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
Phase 2

Los Angeles, California6 trials

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Ellison Clinic at Saint John's

Phase 1/2
ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors

Avenzo Therapeutics Recruiting Site

Phase 1/2
SNV4818 in Participants With Advanced Solid Tumors

The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate

Phase 1/2
Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

START Los Angeles

Phase 1/2
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors

University of California LA

Phase 1/2
To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer

Los Angeles Cancer Network

Phase 2

Birmingham, Alabama4 trials

A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

University of Alabama at Birmingham

Phase 1
A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors

University of Alabama At Birmingham Hospital

Phase 1
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

University of Alabama at Birmingham

Phase 2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

University of Alabama at Birmingham Cancer Center

Phase 2

Duarte, California4 trials

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

City of Hope - Duarte

Phase 1/2
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

City of Hope

Phase 1
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

City of Hope (City of Hope National Medical Center, City of Hope Medical Center)

Phase 1
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

City of Hope Comprehensive Cancer Center

Phase 1

New Haven, Connecticut4 trials

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

Yale School of Medicine

Phase 1/2
Rash & Diarrhea Prophylaxis With Capivasertib

Yale University

Phase 2
Study of AVZO-021 in Patients With Advanced Solid Tumors

Yale Cancer Center

Phase 1/2
Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer

Yale New Haven Hospital

Phase 1

Anchorage, Alaska2 trials

A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)

Alaska Womens Cancer Care ( Site 0037)

Phase 2
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Alaska Oncology and Hematology

Phase 3

Gilbert, Arizona2 trials

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

Banner MD Anderson Cancer Center

Phase 3
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

Research Site

Phase 3

Scottsdale, Arizona2 trials

A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors

Mayo Clinic of Scottsdale

Phase 1
Study of PF-07248144 in Advanced or Metastatic Solid Tumors

HonorHealth

Phase 2

Tucson, Arizona2 trials

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

The University of Arizona Cancer Center

Phase 1
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

University of Arizona

Phase 1/2

Chicago, Illinois2 trials

A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

Northwestern Memorial Hospital

Phase 1
Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors

University of Chicago Medicine Comprehensive Cancer Center

Phase 1

St Louis, Missouri2 trials

Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score

Washington University School of Medicine

Phase 2
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Siteman Cancer Center at Washington University

Phase 2

Chandler, Arizona1 trial

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Ironwood Cancer & Research Centers

Phase 3

Anaheim, California1 trial

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

Los Angeles Cancer Network - Anaheim

Phase 2

Greenbrae, California1 trial

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

Marin Cancer Care Inc

Phase 3

Orange, California1 trial

Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer

Chao Family Comprehensive Cancer Center, University of California, Irvine

Phase 2

Denver, Colorado1 trial

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Sarah Cannon Research Institute (Scri) At Health One

Phase 1

Orlando, Florida1 trial

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Florida Cancer Specialists

Phase 1/2

Sarasota, Florida1 trial

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

Florida Cancer Specialists

Phase 1

Tampa, Florida1 trial

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

Moffitt Cancer Center

Phase 2

Atlanta, Georgia1 trial

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Emory University

Phase 1/2

Iowa City, Iowa1 trial

BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer

University of Iowa Hospitals and Clinics

Phase 1

Boston, Massachusetts1 trial

VS-6766+Abema+Fulv in Met HR+/HER- BC

Massachusetts General Hospital Cancer Center

Phase 1/2

Rochester, Minnesota1 trial

Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer

Biotheryx Investigative Site

Phase 1

Lebanon, New Hampshire1 trial

Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor

Dartmouth Hitchcock Medical Center

Phase 2

Basking Ridge, New Jersey1 trial

A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Phase 1/2

Cleveland, Ohio1 trial

Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer

University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.